Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine in mild to moderate COVID-19
NCT05947812Phase 2Unknown
- Sponsor
- 60 Degrees Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Tafenoquine with Placebo (2 arms). Primary endpoint: Time to sustained clinical recovery from COVID-19 symptoms at Day 28. Status: unknown.
02
Drugs
tafenoquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05947812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947812.